By Muhunthan Thillai (CEO - Qureight)2025-04-22T09:00:39
Deep learning is transforming lung disease treatment by enabling earlier diagnosis, precise monitoring and more efficient clinical trials. This article explores how AI-driven imaging is accelerating drug development and improving patient outcomes.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2026-03-25T15:00:00 2026-03-25T16:00:00
Sponsored by Yokogawa
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
2023-03-20T13:41:33
Sponsored by Bio-Techne
2024-05-07T13:11:19
Sponsored by BellBrook Labs
2025-09-24T14:00:00
Sponsored by Eurofins Discovery
2023-05-10T11:18:16
Sponsored by Revvity
Site powered by Webvision Cloud